Suzhou Lychix Bio Completes Series A-1 and A-2 Funding Rounds to Accelerate Innovation in Life Science Tools and In Vitro Diagnostics

VCBeat learned at the earliest opportunity,Suzhou Lychix Biotechnology Co., Ltd. (hereinafter referred to as “Suzhou Lychix”) has recently completed its Series A-1 and Series A-2 financing rounds in succession.Among these, the Series A-1 financing round was co-led by IDG Capital and Langyu Capital, while the Series A-2 round was co-led by IDG Capital and PerkinElmer Ventures. The funds raised from both rounds will be primarily used to further invest in research and development, build up the talent team, and advance product commercialization.

Suzhou Lychix, established in 2018, is a company providing advanced research tools for life sciences, with a continuous focus on developing high-efficiency technology platforms to mine massive, high-resolution life science data. Currently, the company has built multiple application platforms based on its core technology platform, μ-MFP (Micro-scaled Multi Physics coupled Force), includingUltra-High Sensitivity Biomolecule Detection Platform, suitable for multi-analyte combined testingMultiplex Magnetic-Fluorescent Encoded Microsphere Platformand applications in single-cell multi-omicsHigh-Throughput Single-Cell Parallel Manipulation Platform。

Lychix’s ultra-high-sensitivity single-molecule immunoassay platform offers advantages such as high resolution, high sensitivity, low background signal, low sample volume requirements, and short analysis time. It demonstrates significant benefits in drug development areas including cell pathway characterization, cytokine detection, protein–protein interaction studies, drug metabolism, and T-cell activation analysis. The platform is also widely applicable in in vitro diagnostics for neurology, oncology, cardiology, reproductive health, ophthalmology, and infectious diseases, playing a crucial role in early diagnosis of related diseases and the detection of biomarkers at extremely low levels.

PerkinElmer is dedicated to delivering unique solutions for application markets such as diagnostics and life sciences. In the life sciences sector, it provides comprehensive solutions encompassing detection technologies, instrument platforms, reagents and consumables, and related services across molecular, cellular, and in vivo levels. Its portfolio includes Cisbio Bioassays, Horizon, Nexcelom Bioscience, and SIRION Biotech, with its footprint in the life sciences field continuously expanding. In the field of in vitro diagnostics, its product businesses include reproductive health and independent clinical laboratory services, clinical infectious disease diagnostics and blood transfusion safety, applied genetic analysis, and diagnostics for autoimmune and allergic diseases. The company’s operations also cover product research and development, clinical registration, manufacturing and quality control, channel promotion, and investments and mergers and acquisitions.

With the addition of PerkinElmer Ventures, Suzhou Lychix is poised to expand its footprint across more application areas and continue developing technological platforms that enhance resolution and data throughput in life sciences research, thereby making greater contributions to life sciences research and in vitro diagnostics.

Langyu Capital is an early-stage innovative pharmaceutical investment firm dedicated to advancing breakthrough life science technologies. We are committed to continuously identifying the world’s most cutting-edge scientific innovations and partnering with exceptional collaborators to accelerate the global commercialization of transformative therapies, thereby addressing unmet clinical needs. Backed by an international team of professionals and scientific advisors, Langyu Capital leverages a global perspective and an extensive resource network. Guided by principles of integrity, openness, and inclusivity, we look forward to forging deep collaborations with scientists, research institutions, and startups in the global innovative drug sector.

PKI Ventures, an industry-focused investment fund initiated by the U.S.-listed company PerkinElmer, specializes in investments within the healthcare sector. PKI Ventures focuses on outstanding innovative enterprises in China’s in vitro diagnostics (IVD) and life sciences industries. Leveraging PerkinElmer’s global industry resources and the fund management team’s extensive expertise accumulated over years in these specialized sectors, PKI Ventures provides capital and professional resource support to domestic IVD and life sciences innovators, thereby fostering innovation and development in China’s IVD and life sciences industries.

IDG Capital is a globally leading private equity investment firm. With nearly 30 years of development, the company has accumulated over RMB 150 billion in assets under management. IDG Capital focuses on leading enterprises in sectors such as the internet, new consumption and services, culture and entertainment, healthcare, advanced manufacturing, and clean energy. Its investment scope covers all stages, including early-stage, growth-stage, mature-stage, and mergers and acquisitions/restructuring, with investment sizes ranging from millions to hundreds of millions of US dollars.